Search Results
The product title you are looking for is no longer available. Other similar products that may interest you are listed below:
| Title | Publication Date | Price | Relevance |
|---|---|---|---|
| Merck & Co Inc-Deals & Alliances Report | Mar 2011 | £380 | 100% |
| Merck & Co Inc-Detailed Product Pipeline | Mar 2011 | £475 | 98% |
| Merck & Co Inc-Therapeutic Competitors | Mar 2011 | £220 | 94% |
| Galapagos NV – Product Pipeline Review H2 2011 |
Nov 2011 | £315 | 86% |
| Ariad Pharmaceuticals, Inc. – Product Pipeline Review H2 2011 |
Nov 2011 | £315 | 86% |
| Rheumatoid Arthritis Therapeutics Pipeline Assessment and Market Forecasts to 2018 |
Oct 2011 | £2,215 | 85% |
| Rigel Pharmaceuticals, Inc. – Product Pipeline Review H2 2011 |
Dec 2011 | £315 | 85% |
| Mylan Inc. – Product Pipeline Review H2 2011 |
Nov 2011 | £315 | 85% |
| GTx, Inc. - Pharmaceuticals & Healthcare Deals and Alliances Profile |
Jul 2009 | £160 | 85% |
| Glaucoma Pharmaceuticals | Feb 2010 | £2,500 | 85% |
| Companion Diagnostics | Sep 2011 | £2,655 | 84% |
| DPP IV Inhibitors | Sep 2011 | £2,655 | 84% |
| Hyperlipidemia - Pipeline Review H2 2011 |
Aug 2011 | £315 | 83% |
| Osteosarcoma Therapeutics Pipeline Assessment and Market Forecasts to 2017 |
May 2011 | £1,265 | 83% |
| Cubist Pharmaceuticals, Inc. - Pharmaceuticals & Healthcare Deals and Alliances Profile |
Jul 2009 | £160 | 82% |
| Cubist Pharmaceuticals, Inc. – Product Pipeline Review H2 2011 |
Nov 2011 | £315 | 82% |
| Emerging Cancer Vaccines Market to 2017 Novel, First-in-Class Vaccines in Phase Ii and Phase Iii Pipeline to Shape The Future Cancer Vaccines Market |
Oct 2011 | £2,215 | 82% |
| Portola Pharmaceuticals, Inc. – Product Pipeline Review H2 2011 |
Dec 2011 | £315 | 82% |
| Endometrial Cancer Therapeutics Pipeline Assessment and Market Forecasts to 2017 |
Mar 2011 | £1,265 | 82% |
| Oncothyreon - Product Pipeline Review Q4 2010 |
Dec 2010 | £315 | 81% |
| Insomnia Therapeutics Pipeline Assessment and Market Forecasts to 2018 |
Dec 2011 | £2,215 | 81% |
| Inflammatory Bowel Disease Therapeutics | Apr 2010 | £2,500 | 81% |
| Systemic Lupus Erythematosus Therapeutics (SLE) Pipeline Assessment and Market Forecasts to 2018 |
Oct 2011 | £2,215 | 81% |
| Geron Corporation – Product Pipeline Review H2 2011 |
Oct 2011 | £315 | 81% |
| Spinal Surgery | Oct 2011 | £2,845 | 80% |
| CSL Limited – Product Pipeline Review H2 2011 |
Nov 2011 | £315 | 80% |
| Cancer Therapies Global Market Opportunities |
Nov 2009 | £1,895 | 80% |
| Acute Coronary Syndrome | Apr 2010 | £2,180 | 80% |
| Hypercholesterolemia Therapeutics Pipeline Assessment and Market Forecasts to 2017 |
Apr 2011 | £1,265 | 80% |
| Infertility - Pipeline Review H2 2011 |
Sep 2011 | £315 | 80% |
